- Home
- SONN vs CMMB Comparison
SONN vs CMMB Comparison
Compare SONN & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONN
- CMMB
- Stock Information
- Founded
- SONN N/A
- CMMB 2004
- Country
- SONN United States
- CMMB Israel
- Employees
- SONN N/A
- CMMB N/A
- Industry
- SONN Biotechnology: Pharmaceutical Preparations
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- SONN Health Care
- CMMB Health Care
- Exchange
- SONN Nasdaq
- CMMB Nasdaq
- Market Cap
- SONN 21.4M
- CMMB 22.0M
- IPO Year
- SONN N/A
- CMMB N/A
- Fundamental
- Price
- SONN $5.90
- CMMB $3.03
- Analyst Decision
- SONN Strong Buy
- CMMB Strong Buy
- Analyst Count
- SONN 1
- CMMB 2
- Target Price
- SONN $20.00
- CMMB $26.50
- AVG Volume (30 Days)
- SONN 825.4K
- CMMB 142.4K
- Earning Date
- SONN 08-13-2025
- CMMB 11-13-2025
- Dividend Yield
- SONN N/A
- CMMB N/A
- EPS Growth
- SONN N/A
- CMMB N/A
- EPS
- SONN N/A
- CMMB N/A
- Revenue
- SONN $1,000,000.00
- CMMB N/A
- Revenue This Year
- SONN $5,376.22
- CMMB N/A
- Revenue Next Year
- SONN N/A
- CMMB N/A
- P/E Ratio
- SONN N/A
- CMMB N/A
- Revenue Growth
- SONN 1689.52
- CMMB N/A
- 52 Week Low
- SONN $1.08
- CMMB $2.96
- 52 Week High
- SONN $19.30
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- SONN 74.18
- CMMB 26.72
- Support Level
- SONN $2.71
- CMMB $2.96
- Resistance Level
- SONN $4.35
- CMMB $3.14
- Average True Range (ATR)
- SONN 0.58
- CMMB 0.22
- MACD
- SONN 0.22
- CMMB 0.01
- Stochastic Oscillator
- SONN 80.96
- CMMB 8.09
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.